SANUWAVE Health, Inc. (OTCMKTS:SNWV) Files An 8-K Results of Operations and Financial Condition

Item 2.02Results of Operations and Financial Condition.

On April 4, 2017, SANUWAVE Health, Inc., a Nevada Corporation
(the “Company”), announced its financial results for the year
ended December 31, 2016 and provided a business update. A copy of
the related press release is furnished as Exhibit 99.
to this Form 8-K.

The information in this Item 2.02 of this Current Report on
Form 8-K and the exhibits attached hereto shall not be deemed to
be “filed” for purposes of Section 18 of the Securities Exchange
Act of 1934, as amended, and shall not be deemed incorporated by
reference in any filing under the Securities Act of 1933, as
amended, except as shall be expressly set forth by specific
reference in such filing.

Item 7.01 Regulation FD Disclosure

The Company hosted a conference call with investors on April
4, 2017 at 10 a.m., Eastern Time, to discuss the financial
results for the year ended December 31, 2016 and provide a
business update. A copy of managements prepared remarks is
furnished as Exhibit 99.2.

The information in this Item 7.01 of this Current Report on Form
8-K and the exhibit attached hereto shall not be deemed to be
filed for purposes of Section 18 of the Securities Exchange Act
of 1934, as amended, and shall not be deemed incorporated by
reference in any filing under the Securities Act of 1933, as
amended, except as shall be expressly set forth by specific
reference in such filing.

Item 9.01Financial Statements and Exhibits.

About SANUWAVE Health, Inc. (OTCMKTS:SNWV)

SANUWAVE Health, Inc. is an acoustic pressure shock wave technology company using a system of noninvasive, high-energy, acoustic pressure shock waves for indications, such as regenerative medicine and other applications. The Company is focused on regenerative medicine utilizing noninvasive (extracorporeal), acoustic pressure shock waves to produce a biological response resulting in the body healing itself through the repair and regeneration of skin, musculoskeletal tissue and vascular structures. Its lead regenerative product in the United States is the dermaPACE device, used for treating diabetic foot ulcers. Its portfolio of healthcare products and product candidates activate biologic signaling and angiogenic responses, including new vascularization and microcirculatory improvement, enabling to restore the body’s normal healing processes and regeneration. It is focused on developing its Pulsed Acoustic Cellular Expression (PACE) technology to activate healing in wound conditions.

SANUWAVE Health, Inc. (OTCMKTS:SNWV) Recent Trading Information

SANUWAVE Health, Inc. (OTCMKTS:SNWV) closed its last trading session up +0.005 at 0.127 with shares trading hands.